RuncheyResearch
Back to Forecasting
WVEActive

Will FDA indicate willingness to accept biomarker endpoints for WVE-006 accelerated approval by mid-2026?

Resolves September 30, 2026(174d)
IG: 0.80

Current Prediction

36%
Likely No
Model Agreement95%
Predictions9 runs
Last UpdatedApril 8, 2026

Why This Question Matters

FDA feedback on WVE-006 accelerated approval pathway is a binary event identified as CRITICAL by the Regulatory Reader. Acceptance would dramatically shorten the AATD program timeline and reduce capital requirements. Rejection would force a longer, more expensive Phase III, compressing the already-stretched runway.

REGULATORY_EXPOSUREFUNDING_FRAGILITY

Prediction Distribution

0%25%50%75%100%
opus
sonnet
haiku
Range: 31% – 44%Aggregate: 36%
Individual Predictions(9 runs)
opusRun 1
44%

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Rare disease with strong unmet need provides partial support, but novel mechanism class faces heightened scrutiny creates counterweight. Probability: 0.44.

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet needNovel mechanism class faces heightened scrutiny
opusRun 2
36%

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Rare disease with strong unmet need provides partial support, but novel mechanism class faces heightened scrutiny creates counterweight. Probability: 0.36.

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet needNovel mechanism class faces heightened scrutiny
opusRun 3
36%

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Rare disease with strong unmet need provides partial support, but novel mechanism class faces heightened scrutiny creates counterweight. Probability: 0.36.

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet needNovel mechanism class faces heightened scrutiny
sonnetRun 1
31%

Base rate evidence: novel mechanism class faces heightened scrutiny. Partial offset from rare disease with strong unmet need. FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Probability: 0.31.

Novel mechanism class faces heightened scrutinyFDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet need
sonnetRun 2
44%

Base rate evidence: novel mechanism class faces heightened scrutiny. Partial offset from rare disease with strong unmet need. FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Probability: 0.44.

Novel mechanism class faces heightened scrutinyFDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet need
sonnetRun 3
33%

Base rate evidence: novel mechanism class faces heightened scrutiny. Partial offset from rare disease with strong unmet need. FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Probability: 0.33.

Novel mechanism class faces heightened scrutinyFDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet need
haikuRun 1
36%

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Balance of evidence suggests 0.36 probability. Primary support: rare disease with strong unmet need. Main counterargument: novel mechanism class faces heightened scrutiny.

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet needNovel mechanism class faces heightened scrutiny
haikuRun 2
41%

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Balance of evidence suggests 0.41 probability. Primary support: rare disease with strong unmet need. Main counterargument: novel mechanism class faces heightened scrutiny.

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet needNovel mechanism class faces heightened scrutiny
haikuRun 3
31%

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertainty. Balance of evidence suggests 0.31 probability. Primary support: rare disease with strong unmet need. Main counterargument: novel mechanism class faces heightened scrutiny.

FDA precedent for biomarker endpoints in AATD exists but novel mechanism class creates additional uncertaintyRare disease with strong unmet needNovel mechanism class faces heightened scrutiny

Resolution Criteria

Resolves YES if Wave discloses FDA feedback indicating acceptance of biomarker endpoints for accelerated approval of WVE-006 by September 30, 2026. Resolves NO if FDA requires traditional clinical endpoints or if no feedback is disclosed.

Resolution Source

Wave Life Sciences press release, SEC filing, or earnings call disclosure

Source Trigger

FDA feedback on WVE-006 accelerated approval pathway expected mid-2026; binary outcome for AATD program timeline and value

regulatory-readerREGULATORY_EXPOSURECRITICAL
View WVE Analysis

Full multi-lens equity analysis